Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nephropathy in type 2 diabetes.

E Ritz1

  • 1Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.

Journal of Internal Medicine
|March 19, 1999
PubMed
Summary
This summary is machine-generated.

Diabetic nephropathy is a leading cause of kidney failure in Europe. Effective management of blood pressure and glycemic control are crucial for preventing its progression, yet many patients receive inadequate treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992
Same journal

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same journal

Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.

Journal of internal medicine·2026
Same journal

Multicenter validation of a severity index model for predicting postoperative acute kidney injury.

Journal of internal medicine·2026
Same journal

The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.

Journal of internal medicine·2026
Same journal

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same journal

Authors' reply: Myasthenia gravis following the initiation of statin therapy.

Journal of internal medicine·2026
See all related articles

Area of Science:

  • Nephrology
  • Diabetology
  • Public Health

Background:

  • End-stage renal failure (ESRF) in diabetic patients, primarily type 2, is the leading cause of renal replacement therapy in Western Europe.
  • Diabetic glomerulosclerosis is common, but non-diabetic renal disease and atypical presentations are increasingly significant.
  • Key risk factors for diabetic nephropathy include genetic predisposition, glycemic control, blood pressure, and smoking.

Purpose of the Study:

  • To highlight the prevalence and risk factors of diabetic nephropathy in type 2 diabetes.
  • To emphasize the critical role of hypertension management in slowing disease progression.
  • To underscore the gap in adequate treatment and advocate for improved patient management strategies.

Main Methods:

  • Literature review and analysis of risk factors and treatment outcomes for diabetic nephropathy.

Related Experiment Videos

  • Examination of the role of hypertension and antihypertensive therapies, including ACE inhibitors.
  • Assessment of current treatment adequacy in Western Europe based on the St Vincent declaration.

    • Main Results:

    • Approximately 80% of type 2 diabetes diagnoses reveal abnormal blood pressure profiles.
    • Hypertension is the primary driver of diabetic nephropathy progression and is amenable to intervention.
    • ACE inhibitors are a preferred antihypertensive, but monotherapy often fails to meet blood pressure goals.

    Conclusions:

    • Diabetic nephropathy is largely preventable, but current treatment rates are insufficient.
    • Improved patient management and interdisciplinary collaboration are essential for preventing diabetic complications.
    • Urgent novel approaches are needed to align with preventative health goals for diabetic patients.